| Non-Small Cell Lung Carcinoma
Augtyro vs Braftovi
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Augtyro vs Braftovi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBraftovi has a higher rate of injection site reactions vs Augtyro based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Braftovi but not Augtyro, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Augtyro
Braftovi
At A Glance
Oral
Once daily x14 days, then twice daily
ROS1/TRK inhibitor
Oral
Once daily
BRAF inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- Solid Neoplasm
- melanoma
- Colorectal Carcinoma
- Non-Small Cell Lung Carcinoma
Dosing
Non-Small Cell Lung Carcinoma, Solid Neoplasm 160 mg orally once daily for 14 days, then increase to 160 mg twice daily, with or without food, until disease progression or unacceptable toxicity.
melanoma, Non-Small Cell Lung Carcinoma 450 mg (six 75 mg capsules) orally once daily in combination with binimetinib until disease progression or unacceptable toxicity.
Colorectal Carcinoma 300 mg (four 75 mg capsules) orally once daily until disease progression or unacceptable toxicity, in combination with biweekly cetuximab and mFOLFOX6 or FOLFIRI, or weekly cetuximab.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Dizziness, dysgeusia, peripheral neuropathy, constipation, dyspnea, fatigue, ataxia, cognitive impairment, muscular weakness, nausea.
Serious Pneumonia, dyspnea, pleural effusion, hypoxia.
Most common (>=25%) Fatigue, nausea, vomiting, diarrhea, abdominal pain, arthralgia, peripheral neuropathy, decreased appetite, rash, constipation, musculoskeletal pain, hemorrhage, pyrexia.
Serious New primary malignancies, cardiomyopathy, hepatotoxicity, hemorrhage, uveitis, QT prolongation, embryo-fetal toxicity.
Pharmacology
Repotrectinib is a kinase inhibitor of ROS1 and tropomyosin receptor tyrosine kinases (TRKA, TRKB, TRKC); fusion proteins containing these domains drive tumorigenic potential through hyperactivation of downstream signaling pathways leading to unconstrained cell proliferation.
Encorafenib is a kinase inhibitor that targets BRAF V600E as well as wild-type BRAF and CRAF, blocking constitutively activated BRAF kinase signaling driven by BRAF V600 mutations that stimulates tumor cell growth; in combination with binimetinib, it targets two kinases in the RAS/RAF/MEK/ERK pathway for greater anti-tumor activity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Augtyro
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Braftovi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Augtyro
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Braftovi
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Augtyro
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Braftovi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Augtyro.
$0/fillfill
Braftovi Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AugtyroView full Augtyro profile
BraftoviView full Braftovi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.